Abvc Biopharma Stock Current Liabilities
| ABVC Stock | USD 1.48 0.13 9.63% |
ABVC Biopharma fundamentals help investors to digest information that contributes to ABVC Biopharma's financial success or failures. It also enables traders to predict the movement of ABVC Stock. The fundamental analysis module provides a way to measure ABVC Biopharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to ABVC Biopharma stock.
The current year's Total Current Liabilities is expected to grow to about 6.2 M, whereas Non Current Liabilities Total is forecasted to decline to about 407.7 K. ABVC | Current Liabilities |
ABVC Biopharma Company Current Liabilities Analysis
ABVC Biopharma's Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
ABVC Current Liabilities Driver Correlations
Understanding the fundamental principles of building solid financial models for ABVC Biopharma is extremely important. It helps to project a fair market value of ABVC Stock properly, considering its historical fundamentals such as Current Liabilities. Since ABVC Biopharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of ABVC Biopharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of ABVC Biopharma's interrelated accounts and indicators.
Click cells to compare fundamentals
ABVC Current Liabilities Historical Pattern
Today, most investors in ABVC Biopharma Stock are looking for potential investment opportunities by analyzing not only static indicators but also various ABVC Biopharma's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current liabilities growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of ABVC Biopharma current liabilities as a starting point in their analysis.
ABVC Biopharma Current Liabilities |
| Timeline |
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
| Competition |
ABVC Total Current Liabilities
Total Current Liabilities |
|
In accordance with the recently published financial statements, ABVC Biopharma has a Current Liabilities of 0.0. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The current liabilities for all United States stocks is 100.0% higher than that of the company.
Did you try this?
Run Equity Analysis Now
Equity AnalysisResearch over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |
| All Next | Launch Module |
ABVC Fundamentals
| Return On Equity | -1.92 | ||||
| Return On Asset | -0.43 | ||||
| Operating Margin | (906.06) % | ||||
| Current Valuation | 17.64 M | ||||
| Shares Outstanding | 10.56 M | ||||
| Shares Owned By Insiders | 26.97 % | ||||
| Shares Owned By Institutions | 2.43 % | ||||
| Number Of Shares Shorted | 532.98 K | ||||
| Price To Book | 1.36 X | ||||
| Price To Sales | 75.52 X | ||||
| Revenue | 152.43 K | ||||
| Gross Profit | 350.71 K | ||||
| EBITDA | (8.19 M) | ||||
| Net Income | (10.52 M) | ||||
| Cash And Equivalents | 2.99 M | ||||
| Cash Per Share | 0.09 X | ||||
| Total Debt | 2.45 M | ||||
| Debt To Equity | 0.34 % | ||||
| Current Ratio | 2.68 X | ||||
| Book Value Per Share | 1.06 X | ||||
| Cash Flow From Operations | (4.06 M) | ||||
| Short Ratio | 0.92 X | ||||
| Earnings Per Share | (2.43) X | ||||
| Target Price | 2.02 | ||||
| Number Of Employees | 16 | ||||
| Beta | 0.77 | ||||
| Market Capitalization | 15.63 M | ||||
| Total Asset | 14.94 M | ||||
| Retained Earnings | (65.42 M) | ||||
| Working Capital | (4.28 M) | ||||
| Net Asset | 14.94 M |
About ABVC Biopharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze ABVC Biopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ABVC Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ABVC Biopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards ABVC Biopharma in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, ABVC Biopharma's short interest history, or implied volatility extrapolated from ABVC Biopharma options trading.
Pair Trading with ABVC Biopharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ABVC Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ABVC Biopharma will appreciate offsetting losses from the drop in the long position's value.Moving against ABVC Stock
| 0.48 | VKTX | Viking Therapeutics Potential Growth | PairCorr |
| 0.47 | LLY | Eli Lilly Earnings Call This Week | PairCorr |
| 0.44 | ELYM | Eliem Therapeutics | PairCorr |
| 0.44 | NRSNW | NeuroSense Therapeutics | PairCorr |
The ability to find closely correlated positions to ABVC Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ABVC Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ABVC Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ABVC Biopharma to buy it.
The correlation of ABVC Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ABVC Biopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ABVC Biopharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ABVC Biopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out ABVC Biopharma Piotroski F Score and ABVC Biopharma Altman Z Score analysis. For information on how to trade ABVC Stock refer to our How to Trade ABVC Stock guide.You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Complementary Tools for ABVC Stock analysis
When running ABVC Biopharma's price analysis, check to measure ABVC Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ABVC Biopharma is operating at the current time. Most of ABVC Biopharma's value examination focuses on studying past and present price action to predict the probability of ABVC Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ABVC Biopharma's price. Additionally, you may evaluate how the addition of ABVC Biopharma to your portfolios can decrease your overall portfolio volatility.
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges |
Is ABVC Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ABVC Biopharma. If investors know ABVC will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ABVC Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.43) | Revenue Per Share 0.035 | Quarterly Revenue Growth (1.00) | Return On Assets (0.43) | Return On Equity (1.92) |
The market value of ABVC Biopharma is measured differently than its book value, which is the value of ABVC that is recorded on the company's balance sheet. Investors also form their own opinion of ABVC Biopharma's value that differs from its market value or its book value, called intrinsic value, which is ABVC Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ABVC Biopharma's market value can be influenced by many factors that don't directly affect ABVC Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ABVC Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if ABVC Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ABVC Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.